Abstract: The present disclosure relates to the identification of a QTL associated with high ethanol tolerance in Saccharomyces spp. More specifically, it relates to specific alleles of MKT1 and APJ1 possibly combined with a specific allele of SWS2 that are important in obtaining a high ethanol tolerance in Saccharomyces spp. It relates further to the use of such alleles in the construction of high ethanol tolerant strains, and the use of these alleles in screening for ethanol tolerance.

Abstract: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HN2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections.

Abstract: The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognized by a CD4+ T cell, more specifically, of an allergen or autoantigen, coupled, optionally, through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides may be used for the prevention or treatment of immune disorders, more specifically, of allergic disorders or autoimmune diseases. The present invention thus provides methods of treatment or preventing immune disorders by using such peptides.

Abstract: A series of monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

Abstract: A semiconductor device comprising a graphene layer, a graphene oxide layer overlaying the graphene layer, and a high-k dielectric layer overlaying the graphene oxide layer is provided, as well as a method for producing the same. The method results in a graphene chemical functionalization that efficiently and uniformly seeds ALD growth, preserves the underlying graphene structure, and achieves desirable dielectric properties such as low leakage current and high capacitance.

Abstract: The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm.

Abstract: A method for measuring a concentration of a biogenic substance in a living body includes steps of: preparing an apparatus including a light source, a substrate which has periodic metal structures and generates surface enhanced Raman scattering light by being irradiated with light from the light source, and spectroscopic means which disperses and detects the light, wherein the periodic metal structure is arranged with first and second distances in first and second direction respectively, the first distance is set to generate surface plasmon by matching a phase of the light from the light source, and the second distance is smaller than the first distance and is set between 300 nm and 350 nm; irradiating the substrate with the light from the light source to generate the surface enhanced Raman scattering; detecting the scattering with the spectroscopic means; and calculating the concentration of the biogenic substance based on the scattering.

Abstract: The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.

Abstract: The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1. The present invention also relates to a method for their preparation, as well as to pharmaceutical compositions thereof. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and auto-immune disorders, organ and cells transplant rejections.

Abstract: The invention relates to substituted 2-aminoimidazoles and their imidazo[1,2-a]pyrimidinium salts precursors being active against biofilm formation. The invention also relates to imidazo[1,2-a]pyrimidinium salts bearing an azidoalkyl substituent, and to substituted 2-aminoimidazoles wherein the amino group bears a terminal heterocyclic group such as a triazolyl group which are formed through azide-alkyne Huisgen cycloaddition starting from said imidazo[1,2-a]pyrimidinium salts bearing an azidoalkyl substituent. The invention also relates to a class of N-(azidoalkyl)pyrimidin-2-amines useful as starting materials for the synthesis of said imidazo[1,2-a]pyrimidinium salts bearing an azidoalkyl substituent. The invention also relates to antimicrobial compositions that include a microbial biofilm formation inhibiting amount of such substituted 2-aminoimidazoles or imidazo[1,2-a]pyrimidinium salts in combination with excipients.

Abstract: A series of monocyclic or bicyclic diamine-substituted thieno[2,3-d]pyrimidine and isothiazolo[5,4-d]pyrimidine derivatives are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

Abstract: Compounds that bind to phosphatidylinositol-4-kinase III? (PI4KIII?) and inhibit the binding of PI4KIII? to its substrate and/or inhibit PI4KIII? activity may be used in the treatment and/or prevention of an autoimmune or inflammatory disorder, or organ or cell transplant rejection. A new assay for identifying compounds for use in treating and/or preventing those pathological conditions, which comprises measuring the inhibition of PI4KIII? activity, is also disclosed.

Abstract: Described are medicaments and methods of treating or preventing metabolic bone diseases, such as Critical Illness Related Metabolic Bone Disease or of critical illness induced Osteopenia secondary to ICU Admission by sufficient autophagy inducing compound to inhibit or suppress critical illness enhanced osteoclastogenesis or increased osteoclast differentiation. The methods include administering of an autophagy activating compound to a mammal to: treat or prevent a bone degenerative disorder; slow bone deterioration; restore lost bone; maintain bone mass and/or bone quality or inhibit bone resorption in particularly by inhibiting or reducing a process by which osteoclasts break down bone and release the minerals resulting in a transfer of calcium from bone fluid to the blood. Also described are methods for administering the autophagy activating compound to treat a bone disorder of hyperresorption of bone and/or enhanced activation of osteoclasts.

Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic ?-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

Abstract: A dynamic three-degree-of-freedom actuator/transducer element comprising at least three piezoceramic actuators and force sensors, as integrated stacks, which are preloaded in the housing by a low-stiffness tension bar, and are constrained, by means of a flexible shell, against shear force and torsion moment, whereby the element, when powered by external voltage source, is able to generate a dynamical axial force and displacement and dynamical bending and moment in the two principal tilt degrees of freedom around two orthogonal axes perpendicular to the principal displacement. When subjected to an axial force or a tilting moment, the transducer is able to generate charges that are proportional to the exerted force and moments.

Abstract: A coated implantable medical device is described, wherein the coating comprises a coating matrix and particles of one or more molecular sieves, preferably zeolite of zeogrid particles, optionally loaded with one or more bioactive agents. The coating matrix itself can function as a second drug-carrying interface. The coating comprising the molecular sieve material has an excellent biocompatibility and allows suitable drug delivery into the body of an animal, preferably a mammal and most preferably a human.

Abstract: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.

Abstract: A method for measuring a concentration of a biogenic substance in a living body includes steps of: preparing an apparatus including a light source, a substrate which has periodic metal structures and generates surface enhanced Raman scattering light by being irradiated with light from the light source, and spectroscopic means which disperses and detects the light, wherein the periodic metal structure is arranged with first and second distances in first and second direction respectively, the first distance is set to generate surface plasmon by matching a phase of the light from the light source, and the second distance is smaller than the first distance and is set between 300 nm and 350 nm; irradiating the substrate with the light from the light source to generate the surface enhanced Raman scattering; detecting the scattering with the spectroscopic means; and calculating the concentration of the biogenic substance based on the scattering.

Abstract: An implant free quantum well transistor wherein the doped region comprises an implant region having an increased concentration of dopants with respect to the concentration of dopants of adjacent regions of the substrate, the implant region being substantially positioned at a side of the quantum well region opposing the gate region.

Abstract: The present invention relates to the use of trehalose-6-phosphate synthase to modulate plant growth. More specifically, it relates to the use of a class II trehalose-6-phosphate synthase, comprising both a synthase and a phosphatase-like part to modulate plant growth. Preferably, the activity of trehalose-6-phosphate synthase is down-regulated to obtain an increased plant biomass yield.